FDA recall record

Novum Pharma Novacort Gel Sample Packets recall — FDA D-0433-2017

Subpotent Drug: Out of specification result for pramoxine hydrochloride

Class IIIclassification
D-0433-2017official record ID
Jan 25, 2017report date

Recall record at a glance

Official recordD-0433-2017
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmNovum Pharma, LLC
Report dateJan 25, 2017
Recall initiation dateDec 7, 2016
Quantity6,763 1 gram sample packets
LocationChicago, IL, United States

Official product description

Novacort Gel Sample Packets (2% hydrocortisone acetate, 1% pramoxine HCl), 10-count Carton of 1.0 g sample packets), NDC 69646-704-38 (10 ct. Carton of 1gm samples) / NDC 69646-704-01 (Individual 1gm Samples within Carton), Rx Only, Novum Pharma LLC, Chicago, IL 60654

Why the product was recalled

Subpotent Drug: Out of specification result for pramoxine hydrochloride

Distribution information

Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.